Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer
M Velimirovic, M Brignola, E Chheng, M Smith… - … Treatment Options in …, 2024 - Springer
Opinion Statement Drug-induced pneumonitis is a common adverse event that may occur
during lung cancer systemic therapy. The incidence/prevalence of this side effect has …
during lung cancer systemic therapy. The incidence/prevalence of this side effect has …
Safety of tepotinib challenge after capmatinib-induced pneumonitis in a patient with non-small cell lung cancer harboring MET exon 14 skipping mutation: a case …
LW Tseng, JWC Chang, CE Wu - International Journal of Molecular …, 2022 - mdpi.com
The targeted agents capmatinib and tepotinib provide a new treatment for patients with non-
small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). However …
small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). However …
[HTML][HTML] Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Z Saito, T Imakita, T Ito, I Oi, O Kanai, K Fujita… - Case Reports in …, 2023 - karger.com
Osimertinib, a third-generation tyrosine kinase inhibitor, is the first-line treatment for
metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor …
metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor …
Successful rechallenge twice with different EGFR-TKIs in a patient with lung adenocarcinoma after EGFR-TKI-induced grade 3 stomatitis and interstitial lung disease …
X Liu, K Zhu, Y Xie, J Huang - 2024 - researchsquare.com
Background: Rechallenge with EGFR tyrosine kinase inhibitors (TKIs) can be successful as
a result of different TKI adverse event profiles. Grade 3 stomatitis seriously affects a patient's …
a result of different TKI adverse event profiles. Grade 3 stomatitis seriously affects a patient's …
Zytostatische oder zielgerichtete antineoplastische Medikamente
M Horneber, M Galster, JH Ficker - Im Fokus Onkologie, 2022 - Springer
Alle Modalitäten der Therapie maligner Erkrankungen können potenziell schwerwiegende
und in seltenen Fällen tödlich verlaufende pulmonale Toxizitäten verursachen. Nach den …
und in seltenen Fällen tödlich verlaufende pulmonale Toxizitäten verursachen. Nach den …
Pneumonitis and interstitial lung disease: case report
T Mohammed - Reactions, 1901 - ncbi.nlm.nih.gov
A 71-year-old woman developed pneumonitis and interstitial lung disease during treatment
with osimertinib for lung cancer. The woman, who had history of humerus fracture from …
with osimertinib for lung cancer. The woman, who had history of humerus fracture from …